Development and in vivo efficacy of targeted polymeric inflammation- resolving nanoparticles

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 16, 2013, Pages 6506-6511

  Kamaly, Nazila ^a   Fredman, Gabrielle ^b   Subramanian, Manikandan ^b   Gadde, Suresh ^a   Pesic, Aleksandar ^a   Cheung, Louis ^a   Fayad, Zahi Adel ^c   Langer, Robert ^d   Tabas, Ira ^b   Farokhzad, Omid Cameron ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; LIPOCORTIN 1; MACROGOL; NANOPARTICLE; POLYGLACTIN; POLYMER; PROTEIN AC 2 26; UNCLASSIFIED DRUG; ZYMOSAN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADATION; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; LEG ISCHEMIA; MOUSE; NEUTROPHIL; NONHUMAN; PARTICLE SIZE; PERITONITIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REPERFUSION INJURY; TISSUE INJURY;

ANALYSIS OF VARIANCE; ANIMALS; ANNEXIN A1; COLLAGEN TYPE IV; FEMALE; FLOW CYTOMETRY; HINDLIMB; KINETICS; MICE; MICE, INBRED C57BL; NANOPARTICLES; NANOTECHNOLOGY; NEUTROPHILS; PEPTIDES; PERITONITIS; REPERFUSION INJURY;

EID: 84876255289     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1303377110     Document Type: Article

References (44)

1. Majno G, Joris I (2004) Cells, Tissues, and Disease: Principles of General Pathology (Oxford Univ Press, New York), 2nd Ed, p xxviii, 1005 pp.
2. Medzhitov R (2010) Inflammation 2010: New adventures of an old flame. Cell 140(6): 771-776.
3. Serhan CN, et al. (2007) Resolution of inflammation: State of the art, definitions and terms. FASEB J 21(2):325-332.
4. Serhan CN (2010) Novel lipid mediators and resolution mechanisms in acute inflammation: To resolve or not? Am J Pathol 177(4):1576-1591.
5. Nathan C, Ding A (2010) Nonresolving inflammation. Cell 140(6):871-882.
6. Tabas I, Glass CK (2013) Anti-inflammatory therapy in chronic disease: Challenges and opportunities. Science 339(6116):166-172.
7. Perretti M, D'Acquisto F (2009) Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 9(1):62-70.
8. Bannenberg GL, et al. (2005) Molecular circuits of resolution: Formation and actions of resolvins and protectins. J Immunol 174(7):4345-4355.
9. Schwab JM, Chiang N, Arita M, Serhan CN (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447(7146):869-874.
10. Chiang N, et al. (2008) Anesthetics impact the resolution of inflammation. PLoS One 3(4):e1879.other.
11. Norling LV, et al. (2011) Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol 186(10):5543-5547.
12. Navarro-Xavier RA, et al. (2010) A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J Immunol 184(3): 1516-1525.
13. Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3(1):16-20.
14. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC (2012) Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem Soc Rev 41(7):2971-3010.
15. Farokhzad OC, et al. (2004) Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res 64(21):7668-7672.
16. Farokhzad OC, et al. (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103(16):6315-6320.
17. Hrkach J, et al. (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 4(128):128ra139.
18. Xiao Z, et al. (2012) DNA self-assembly of targeted near-infrared- responsive gold nanoparticles for cancer thermo-chemotherapy. Angew Chem Int Ed Engl 51(47): 11853-11857.
19. Salvador-Morales C, Valencia PM, Gao W, Karnik R, Farokhzad OC (2012) Spontaneous formation of heterogeneous patches on polymer-lipid core-shell particle surfaces during self-assembly. Small 9(4):511-517.
20. Dufton N, et al. (2010) Anti-inflammatory role of the murine formyl-peptide receptor 2: Ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 184(5):2611-2619.
21. Perretti M, et al. (2002) Endogenous lipid-and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med 8(11):1296-1302.
22. Perretti M, Getting SJ, Solito E, Murphy PM, Gao JL (2001) Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics. Am J Pathol 158(6):1969-1973.
23. La M, et al. (2001) Annexin 1 peptides protect against experimental myocardial is-chemia-reperfusion: Analysis of their mechanism of action. FASEB J 15(12):2247-2256.
24. Bandeira-Melo C, et al. (2005) A novel effect for annexin 1-derived peptide ac2-26: Reduction of allergic inflammation in the rat. J Pharmacol Exp Ther 313(3):1416-1422.
25. Gavins FN, et al. (2012) Leukocyte recruitment in the brain in sepsis: involvement of the annexin 1-FPR2/ALX anti-inflammatory system. FASEB J 26(12):4977-4988.
26. Evans HL, et al. (2012) Copper-free click: A promising tool for pre-targeted PET imaging. Chem Commun (Camb) 48(7):991-993.
27. Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) 3(3):1377-1397.
28. Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC (2010) Polymeric nano-particles for drug delivery. Methods Mol Biol 624:163-175.
29. Gu F, et al. (2008) Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 105(7):2586-2591.
30. Chan JM, et al. (2010) Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci USA 107(5):2213-2218.
31. Kalluri R (2003) Basement membranes: Structure, assembly and role in tumour an-giogenesis. Nat Rev Cancer 3(6):422-433.
32. Fishbein I, et al. (2001) Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler Thromb Vasc Biol 21(9):1434-1439.
33. Decuzzi P, Ferrari M (2006) The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 27(30):5307-5314.
34. Westedt U, et al. (2002) Deposition of nanoparticles in the arterial vessel by porous balloon catheters: Localization by confocal laser scanning microscopy and transmission electron microscopy. AAPS PharmSci 4(4):E41.
35. Rothenfluh DA, Bermudez H, O'Neil CP, Hubbell JA (2008) Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat Mater 7(3): 248-254.
36. Serhan CN, Chiang N, Van Dyke TE (2008) Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8(5):349-361.
37. Qiu FH, Wada K, Stahl GL, Serhan CN (2000) IMP and AMP deaminase in reperfusion injury down-regulates neutrophil recruitment. Proc Natl Acad Sci USA 97(8): 4267-4272.
38. Mora-Huertas CE, Fessi H, Elaissari A (2010) Polymer-based nanocapsules for drug delivery. Int J Pharm 385(1-2):113-142.
39. Quintanar-Guerrero D, Allémann E, Fessi H, Doelker E (1998) Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm 24(12):1113-1128.
40. Fredman G, Li Y, Dalli J, Chiang N, Serhan CN (2012) Self-limited versus delayed resolution of acute inflammation: Temporal regulation of pro-resolving mediators and microRNA. Sci Rep 2:639.
41. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: Signals in resolution. Nat Immunol 2(7): 612-619.
42. Perretti M, Dalli J (2009) Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics. Br J Pharmacol 158(4):936-946.
43. Muhs BE, Gagne P, Plitas G, Shaw JP, Shamamian P (2004) Experimental hindlimb ischemia leads to neutrophil-mediated increases in gastrocnemius MMP-2 and-9 activity: A potential mechanism for ischemia induced MMP activation. J Surg Res 117(2): 249-254.
44. Facio FN, Jr., et al. (2011) Annexin 1 mimetic peptide protects against renal ischemia/reperfusion injury in rats. J Mol Med (Berl) 89(1):51-63.